Anthropic says recursive self-improvement is their chosen path for AI advancing AI. I explain the ins and outs. An AI Insider ...

As the race to build ever more powerful artificial intelligence systems accelerates, one of the industry's leading players is ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he insists it will actually ship products.

As AI companies explore systems that can help develop more advanced AI, policymakers are beginning to debate whether new ...

The maker of Claude wants the world to keep one option open. The timing is the tell.

The maker of Claude wants AI labs, including itself, to prepare for a coordinated slowdown if models begin building their own ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

Anthropic has warned that recursive-self-improving AI could be on the horizon, but the truth is the company is more ...

Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using technology ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...